Meeting
2023 ASCO Annual Meeting
The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers.
Authors
Moh'd M. Khushman
Washington University in St. Louis, Siteman Cancer Center, St. Louis, MO
Moh'd M. Khushman , Sharon Wu , Joanne Xiu , Alex Patrick Farrell , Anthony F. Shields , John Marshall , Heinz-Josef Lenz , Michael J. Hall , Jim Abraham , Matthew James Oberley , George W. Sledge Jr., David Spetzler , Ibrahim Halil Sahin , Michael Iglesia , Emil Lou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2620)
DOI
10.1200/JCO.2023.41.16_suppl.2620
Abstract #
2620
Poster Bd #
462
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
First Author: Charlee Nardin
Poster
2023 ASCO Annual Meeting
Melanomas lacking HLA class I expression and response to checkpoint inhibitor.
First Author: Paul B. Chapman
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Assessment of complete pathologic response after neoadjuvant immunotherapy for MSI-H gastrointestinal cancers.
First Author: Kruti Bhagirath Vora
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Venous thromboembolism (VTE) in melanoma patients (pts) on immunotherapy (IO).
First Author: Tamara A. Sussman